LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
13. August 2021 08:50 ET | Recro Pharma, Inc.
Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms ...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
10. August 2021 07:00 ET | Recro Pharma, Inc.
EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Second Quarter 2021 Financial Results
09. August 2021 16:05 ET | Recro Pharma, Inc.
Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue Multiple New Business Agreements Continue to Expand and Diversify Customer Base and Pipeline Company...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
02. August 2021 16:05 ET | Recro Pharma, Inc.
EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
20. Juli 2021 07:00 ET | Recro Pharma, Inc.
EXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Development and Manufacturing Agreement With New Client
13. Juli 2021 07:00 ET | Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants for New Staff
07. Juli 2021 07:00 ET | Recro Pharma, Inc.
EXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
16. Juni 2021 07:00 ET | Recro Pharma, Inc.
EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
02. Juni 2021 07:00 ET | Recro Pharma, Inc.
GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Development Agreement With Astex Pharmaceuticals
18. Mai 2021 07:00 ET | Recro Pharma, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...